RUC. Repositorio da Universidade da Coruña
Publication
Artículo científico (JournalArticle)
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
[Abstract]
Objectives: To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection.
Methods: One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays.
Results: Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility.
Conclusions: We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI22/01212 for J.A.-S., PI17/01482 and PI20/01212 for A.B., PI21/00017 for A.O., and PI18/00501 and PI21/00704 for G.B. integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III, ISCIII). This research was also funded by CIBERINFEC, no. CB21/13/00055 and no. CB21/13/00099 (CIBER de Enfermedades Infecciosas), and by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) ‘A way of making Europe’. The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12 to A.B. and IN607A 2016/22 to G.B.). I.A.-G was financially supported by the Rio Hortega programme (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026)., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22
Project:
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI17-01482
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI17-01482
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20-01212
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI21-00017
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI18-00501
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI21-00704
,
MINECO RD16-0016-0004
,
MINECO RD16-0016-0006
View at: https://hdl.handle.net/2183/45468